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.Serum concentrationa of brcur ched chained amino acids (KM) in naorutes with claedc maple syrup urine diseaee (KUD) in the first 4 days of life.
Although serum levels of B C M are elevated in B U D at the time of diannosim, data on senno levels of unino acids prior to develop ment of symptom8 are very limited. We have meamred serum levels of B C M durinp, the firat 4 days of life in 7 neonates f m m 3 funilies with affzcted offsprin a. Three infants had h6UD and 4 were normal. [413] [414] [415] [416] [417] [418] [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] 1978) . The only physical sign was a fixed kyphosis of the thoracic spine without discomfort. X-ray findings were modest, urinary acid mucopolysaccharides increased. Degradation of sulphated mucopolysaccharides by cultured skin fibroblasts was slowed, 5-glucuronidase activity in serum, leukocytes and fibroblasts abnormally low thus documenting MPS VII. We speculated that this previously unknown late and mild form of MPS VII may exist undetected in the qeneral population. We have now discovered a 15 112 year-old boy with a history of nervous dysfunction and pains who had Alder type granulations. From age 9 b2 to 15 he suffered from back pain. He was minimally hunchbacked at 10 I12 years. Today, he has a partially fixed thoracic kyphosis and complains of a tired back after heavy lifting.
I 6-Glucuronidase was abnormally low in his serum and leukocytes. The parents' 6-glucuronidase was normal in serum but intermediate in leukocytes. These observations document MFS VII as the first monogenic disorder of metabolism known to cause fixed thoracic kyphosis in seemingly healthy juveniles and young adults. As the course of this form of MPS VII is unknown, a search for further patients in young and older adults seems warranted.
FAMILIAL HYPERCHOLESTEROLAEMIA. FACTORS INFLUENCING DRUG COMPLIANCE
Thirty five children with FH, treated with cholestyramine, but without dietary restriction, have been followed for 6-8 years. For those remaining on treatment group mean plasma cholesterol was lowered by 30% in the first year, on a mean dose of 0.4g/Kg/day. In subsequent years group mean reduction varied between 26% and 44%. Compliance with treatment declined with time; after 4 years only 68% remained on treatment, and only 48% by the end of 8 years.
An attempt to identify factors influencing compliance in this group shows: Compliance was better in those starting the drug before the age of 1 0 ( p 70.025) Compliance was not significantly better in those with a family history of premature IHD. Compliance with cholestyramine was no worse than with a more palatable bile acid sequestrant (Secholex). There was no sex difference in compliance rates. Siblings all behaved concordantly. GA is an autosomal recessive disease involving the eyes and type I1 muscle fibers. In the eyes, progressive atrophy of the choroid and retina starts by age 5-9 years and leads to virtual blindness in 20-40 years. Muscular involvement is clinically mild. The patients have 10-20-fold increased plasma ornithine concentrations, caused by lack of ornithine amino-transferase. Elevation of ornithine strongly inhibits arginine-glycine amidinotransferase, and decreases subsequently production of guanidinoacetic acid and creatine. We gave to 6 GA patients per os creatine 0.75-1.5 g divided in 3 daily doses. Muscle biopsies before treatment showed tubular aggreRates and atrophy of type I1 muscle fibers in all but one subject. In control biopsies after 1 year of treatment, the atrophy was almost absent and very few cells contained tubular aggregates. The changes in cell size were highly significant. There was some progression in the choroidoretinal atrophies justified by photographs, but the Goldman visual fields showed some improvement. The treatment caused no side effects in the patients.
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L.MORPHIS*,A.CONSTANTOl'OULOS
and N.MATSANI0-
TIS. First Department o f Pediatrics o f Athens
University. T h e effect o f bilirubin and aminophylline o n protein kinase activity i n rabbit brain. Cyclic AMP dependent protein k i n e activity expressed a s pMoles o f labelled P i (from yjiiP-ATP) incorporated into histone (the substrate) per m g o f protein,per min,following intravenous injection o f bilirubin and/or aminophylline w a s studied in rabbits. I t w a s found that: 1)bilirubin reduces protein kinase activity from 2 4 2 9 2 253 (controls) t o 12702198 pMoles (bilirubin-treated animals),whereas aminophylline promotes i t from 2589+ IYb (controls) t o 3588+3Y3 (aminophylline-treated anFmals).Both reduction arid promotion o f this enzyme activity caused by bilirubin and aminophylline respectively are statistically highly significant ( p < 0.001), 2) CAMP i n vitro and aminophylline i n vivo restore the inhibition o f the enzyme caused b y b i 1 i r u b i n C c~~~: f r o m 12702198 t o 15952221, aminophylline: from 1270+198 t o 21b42265) t o a statistically significant degree ( p ( 0.001). These d a t a a r e in agreement with o u r previous in vitro findings in the literature (Cytobios, 17:1R, lY7b) ,in which bilirubin inhibits protein kinase activity by way o f competition with CAMP.
